Spero Therapeutics (NASDAQ:SPRO) has been assigned a $30.00 target price by Oppenheimer in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. Oppenheimer’s target price suggests a potential upside of 177.26% from the company’s previous close.

Several other equities analysts also recently issued reports on SPRO. Cowen began coverage on Spero Therapeutics in a research report on Monday, November 27th. They issued an “outperform” rating on the stock. Stifel Nicolaus began coverage on Spero Therapeutics in a research report on Monday, November 27th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Bank of America began coverage on Spero Therapeutics in a research report on Monday, November 27th. They issued a “neutral” rating on the stock.

Spero Therapeutics (SPRO) opened at $10.82 on Monday. Spero Therapeutics has a 12-month low of $9.84 and a 12-month high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $0.20 million. research analysts anticipate that Spero Therapeutics will post -6.35 EPS for the current year.

In other news, Director Casper Breum bought 214,285 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,999,990.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joel Sendek bought 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $70,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 649,356 shares of company stock worth $9,090,984. 13.90% of the stock is owned by insiders.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/18/spero-therapeutics-spro-given-a-30-00-price-target-at-oppenheimer.html.

Spero Therapeutics Company Profile

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.